Cardiovascular actions and therapeutic potential of tanshinone IIA

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 3-10

  Gao, Si ^a   Liu, Zhiping ^a   Li, Hong ^a   Little, Peter J ^b   Liu, Peiqing ^a   Xu, Suowen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b RMIT UNIVERSITY   (Australia)

Author keywords

Anti oxidant; Atherosclerosis; Cardiac hypertrophy; Myocardial infarction; Oxidized LDL; Tanshinone IIA

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CRYPTOTANSHINONE; DOXORUBICIN; GLUCONATE CALCIUM; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; SUPEROXIDE DISMUTASE; TANSHINONE I; TANSHINONE IIA; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

ACUTE CORONARY SYNDROME; ANAPHYLACTIC SHOCK; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EFFECT; CAROTID ARTERY LIGATION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HEART INFARCTION; HEART INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; LIPID DIET; LIPID PEROXIDATION; LIPID STORAGE; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL MEMBRANE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATCH CLAMP; PRIORITY JOURNAL; REVIEW; SALVIA MILTIORRHIZA; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DITERPENES, ABIETANE; HUMANS; TREATMENT OUTCOME;

EID: 84155164808     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.041     Document Type: Review

References (96)

1. Han J.Y., Fan J.Y., Horie Y., et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008, 117:280-295.
2. Wang X.H., Morris-Natschke S.L., Lee K.H. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007, 27:133-148.
3. Yagi A., Fujimoto K., Tanonaka K., et al. Possible active components of tan-shen (Salvia miltiorrhiza) for protection of the myocardium against ischemia-induced derangements. Planta Med 1989, 55:51-54.
4. Adams J.D., Wang R., Yang J., et al. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med 2006, 1:3.
5. Cheng T.O. Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. Int J Cardiol 2006, 113:437-438.
6. Zhou L., Zuo Z., Chow M.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005, 45:1345-1359.
7. Takahashi K., Ouyang X., Komatsu K., et al. Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells. Biochem Pharmacol 2002, 64:745-749.
8. Wu T.W., Zeng L.H., Fung K.P., et al. Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells. Biochem Pharmacol 1993, 46:2327-2332.
9. Shu Z.Y., Zhang K., Ye X.Y., et al. Combination of naloxone, tanshinone and touch treatment on hypoxic ischemic encephalopathy of neonate. Res Int Trad Chin West Med 2010, 3:133-134.
10. Hao H., Wang G., Cui N., et al. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med 2006, 72:1311-1317.
11. Yu X.Y., Lin S.G., Zhou Z.W., et al. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr Drug Metab 2007, 8:325-340.
12. Li P., Wang G.J., Li J., et al. Identification of tanshinone IIA metabolites in rat liver microsomes by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2006, 1104:366-369.
13. Bi H.C., Zuo Z., Chen X., et al. Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases. Xenobiotica 2008, 38:185-222.
14. Mao S.J., Jin H., Bi Y.Q., et al. Ion-pair reversed-phase HPLC method for determination of sodium tanshinone IIA sulfonate in biological samples and its pharmacokinetics and biodistribution in mice. Chem Pharm Bull 2007, 55:753-756.
15. Qiao J.P., Hou P.L., Li Y.W., et al. Determination of tanshinone IIA in rat plasma and the pharmacokinetics by RP-HPLC method. Yao Xue Xue Bao 2003, 38:368-370. (in Chinese).
16. Yuan Y., Jiang A.H., Zhou J., et al. The absorption mechanism of tanshinone IIA in rat small intestine. Hua Xi Yao Xue Za Zhi 2002, 17:246-248. (in Chinese).
17. Ueng Y.F., Kuo Y.H., Peng H.C., et al. Diterpene quinone tanshinone IIA selectively inhibits mouse and human cytochrome p4501A2. Xenobiotica 2003, 33:603-613.
18. Qiu F., Zhang R., Sun J., et al. Inhibitory effects of seven components of Danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 2008, 36:1308-1314.
19. Ueng Y.F., Kuo Y.H., Wang S.Y., et al. Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sci 2004, 74:885-896.
20. Yu C., Ye S., Sun H., et al. PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact 2009, 177:58-64.
21. Wang X., Cheung C.M., Lee W.Y., et al. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine 2010, 17:868-875.
22. Chen Y., Tu J.H., He Y.J., et al. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers. Xenobiotica 2009, 39:508-513.
23. Jiang S.X., Zheng L.Y. Sodium tanshinone IIA sulfonate injection induces anaphylactic shock. Yao Wu Bu Liang Fan Ying Za Zhi 2007, 9:61. (in Chinese).
24. Lei Y.H. Transfusing of sodium tanshinone IIA sulfonate results in anaphylactic shock. Nei Mongol Zhong Yi Yao 2008, 27:28. (in Chinese).
25. Liu J., Wang X., Cai Z., et al. Effect of tanshinone IIA on the noncovalent interaction between warfarin and human serum albumin studied by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 2008, 19:1568-1575.
26. Liu J., Chen Z.P. Chemical reaction exists between tanshinone IIA and calcium gluconate transfusion. Hu Li Shi Jian Yu Yan Jiu 2009, 6:63. (in Chinese).
27. Ling S., Dai A., Guo Z., et al. A preparation of herbal medicine Salvia miltiorrhiza reduces expression of intercellular adhesion molecule-1 and development of atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2008, 51:38-44.
28. Tang F., Wu X., Wang T., et al. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vasc Pharmacol 2007, 46:427-438.
29. Chen W.Y., Tang F.T., Chen S.R., et al. Phylactic effect of tanshinone II-A on atherogenesis. Zhong Guo Yao Fang 2008, 19:884-887. (in Chinese).
30. Tang F.T., Cao Y., Wang T.Q., et al. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 2011, 650:275-284.
31. Fang Z.Y., Lin R., Yuan B.X., et al. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci 2007, 81:1339-1345.
32. Fang Z.Y., Lin R., Yuan B.X., et al. Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit. J Ethnopharmacol 2008, 115:217-222.
33. Niu X.L., Ichimori K., Yang X., et al. Tanshinone II-A inhibits low density lipoprotein oxidation in vitro. Free Radic Res 2000, 33:305-312.
34. Jang S.I., Jeong S.I., Kim K.J., et al. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1 beta and IL-6 in activated RAW 264.7 cells. Planta Med 2003, 69:1057-1059.
35. Jang S.I., Kim H.J., Kim Y.J., et al. Tanshinone IIA inhibits LPS-induced NF-kappa B activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 2006, 542:1-7.
36. Lin R., Wang W.R., Liu J.T., et al. Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. J Ethnopharmacol 2006, 108:217-222.
37. Pan C., Lou L., Huo Y., et al. Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways. Ther Adv Cardiovasc Dis 2011, 5:99-111.
38. Wang H., Gao X., Zhang B. Tanshinone: an inhibitor of proliferation of vascular smooth muscle cells. J Ethnopharmacol 2005, 99:93-98.
39. Li X., Du J.R., Yu Y., et al. Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. J Ethnopharmacol 2010, 129:273-279.
40. Pan Y.J., Li X.Y., Yang G.T. Effect of tanshinone II A on the calcineurin activity in proliferating vascular smooth muscle cells of rats. Chin J Int Trad West Med 2009, 29:133-135.
41. Jin U.H., Suh S.J., Chang H.W., et al. Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem 2008, 104:15-26.
42. Du J.R., Li X., Zhang R., et al. Tanshinone inhibits intimal hyperplasia in the ligated carotid artery in mice. J Ethnopharmacol 2005, 98:319-322.
43. Xu S.W., Tang F.T., Le K., et al. Tanshinone IIA inhibits oxidized low-density-lipoprotein induced LOX-1 expression in murine macrophages by reduction of intracellular reactive oxygen species and NF-kappa B activation (Abstract). Circulation 2010, 122:e292.
44. Guo Q. Clinical study of STS on treating patients with acute coronary artery syndrome. Zhong Wai Yi Liao 2010, 12:101. (in Chinese).
45. Wang W.L., Ma B.R., Hu X.S., et al. The effect of tanshinone IIA and simvastatin treating the legs atheromatosis. Chin J Arterioscler 2010, 18:11. (in Chinese).
46. Huang Y.K. Clinical observation on therapeutic effect of tanshinone IIA in treating arteries inflammation. Xian Dai Zhong Xi Yi Jie He Za Zhi 2010, 19:1221-1222. (in Chinese).
47. Guo L.Z., Sun F. Clinical observation on therapeutic effect of tanshinone IIA in treating angina pectoris caused by coronary heart disease. Zhong Wai Yi Liao 2008, 26:62-63. (in Chinese).
48. Zhou W.Y., Wang Y.X., Wang Y., et al. The effects of STS on anti-lipid peroxidized damage and hemorheology of patients with coronary heart disease. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2009, 7:218. (in Chinese).
49. Little P.J., Osman N., O'Brien K.D. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 2008, 19:448-454.
50. Holvoet P., Harris T.B., Tracy R.P., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol 2003, 23:1444-1448.
51. Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207:16-23.
52. Fu J.J., Huang H.Q., Liu J.J., et al. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 2007, 568:213-221.
53. Gao J., Yang G., Pi R., et al. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res 2008, 151:79-87.
54. Zhou G.Y., Zhao B.L., Hou J.W., et al. Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol Res 1999, 40:487-491.
55. Zhao N., Liu Y.Y., Wang F., et al. Cardiotonic pills, a compound Chinese medicine, protects ischemia-reperfusion-induced microcirculatory disturbance and myocardial damage in rats. Am J Physiol Heart Circ Physiol 2010, 298:H1166-H1176.
56. Cao E.H., Liu X.Q., Wang J.J., et al. Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radic Biol Med 1996, 20:801-806.
57. Zhang K.Q., Bao Y., Wu P., et al. Antioxidative components of tanshen (Salvia miltiorrhiza Bung). J Agric Food Chem 1990, 38:1194-1197.
58. Weng X.C., Gordon M.H. Antioxidant activity of quinones extracted from tanshen (Salvia miltiorrhiza Bunge). J Agric Food Chem 1992, 40:1331-1336.
59. Chen T.H., Hsu Y.T., Chen C.H., et al. Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. Mitochondrion 2007, 7:101-105.
60. Zhang H.S., Wang S.Q. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem Pharmacol 2007, 73:1358-1366.
61. Gong Z., Huang C., Sheng X., et al. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 2009, 150:104-113.
62. Hsieh H.L., Sun C.C., Wu C.B., et al. Sphingosine 1-phosphate induces EGFR expression via Akt/NF-kappaB and ERK/AP-1 pathways in rat vascular smooth muscle cells. J Cell Biochem 2008, 103:1732-1746.
63. Lin W.N., Luo S.F., Lin C.C., et al. Differential involvement of PKC-dependent MAPKs activation in lipopolysaccharide-induced AP-1 expression in human tracheal smooth muscle cells. Cell Signal 2009, 21:1385-1395.
64. Murphy J.E., Tedbury P.R., Homer-Vanniasinkam S., et al. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 2005, 182:1-15.
65. Hansson G.K. Atherosclerosis - an immune disease - the Anitschkov Lecture 2007. Atherosclerosis 2009, 202:2-10.
66. Fan G.W., Gao X.M., Wang H., et al. The anti-inflammatory activities of tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol 2009, 113:275-280.
67. Xu W., Yang J., Wu L.M. Cardioprotective effects of tanshinone IIA on myocardial ischemia injury in rats. Pharmazie 2009, 64:332-336.
68. Jones W.K., Brown M., Ren X., et al. NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling?. Cardiovasc Toxicol 2003, 3:229-254.
69. Ren Z.H., Tong Y.H., Xu W., et al. Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine 2009, 17:212-218.
70. Zhang Y., Wei L., Sun D., et al. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab 2010, 12:316-322.
71. Sun D.D., Wang H.C., Wang X.B., et al. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I-Ks) potassium channels. Eur J Pharmacol 2008, 590:317-321.
72. Shan H.L., Li X.L., Pan Z.W., et al. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Clin Pharmacol 2009, 158:1227-1235.
73. Wu G.B., Zhou E.X., Qing D.X. Tanshinone IIA elicited vasodilation in rat coronary arteriole: roles of nitric oxide and potassium channels. Eur J Pharmacol 2009, 617:102-107.
74. Huang K.J., Wang H., Xie W.Z., et al. Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging. Spectrochim Acta A 2007, 68:1180-1186.
75. + channels by sodium tanshinone II-A sulfonate (DS-201) in porcine coronary artery smooth muscle cells. Eur J Pharmacol 2008, 598:9-15.
76. Tong Y., Xu W., Han H., et al. Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXC chemokine receptor 4 axis in a myocardial ischemia model. Phytomedicine 2011, 18:443-450.
77. Yang L., Zou X.J., Gao X., et al. Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med 2009, 41:508-516.
78. Chan P., Liu J.C., Lin L.J., et al. Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med 2011, 39:381-394.
79. Jiang F.L., Feng J., Zheng Z., et al. Effect of tanshinone IIA on myocardial cell apoptosis protein of spontaneously hypertensive rats with left ventricular hypertrophy. Chin J Clin Rehabil 2006, 10:58-60.
80. Fang J., Xu S.W., Wang P., et al. Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine 2010, 18:58-64.
81. Yang L., Zou X.J., Liang Q.S., et al. Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway. Exp Mol Med 2007, 39:65-73.
82. Li Y.S., Wang Z.H., Wang J. Effect of tanshinone II A on angiotensin receptor in hypertrophic myocardium of rats with pressure over-loading. Chin J Int Trad West Med 2008, 28:632-636.
83. Schluter K.D., Wenzel S. Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacol Ther 2008, 119:311-325.
84. Li Y.S., Wang Z.H., Yan L., et al. Effect of tashinone on nitric oxide synthase in hypertrophic cardiomyocyte of rats suffered abdominal aorta constriction. Zhongguo Zhong Yao Za Zhi 2008, 33:1446-1450. (in Chinese).
85. Zhou D.X., Liang Q.S., He X.X., et al. Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A. Chin J Chin Mater Med 2008, 33:936-939.
86. Li S.S., Feng J., Zheng Z., et al. Effect of sodium tanshinone II A sulfonate on phosphorylation of extracellular signal-regulated kinase 1/2 in angiotensin II-induced hypertrophy of myocardial cells. Chin J Integr Med 2008, 14:123-127.
87. Li Y., Yang Y., Yu D., et al. The effect of tanshinone IIA upon the TGF-beta1/Smads signaling pathway in hypertrophic myocardium of hypertensive rats. J Huazhong Univ Sci Technolog Med Sci 2009, 29:476-480.
88. Hong H.J., Liu J.C., Cheng T.H., et al. Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt pathway in neonatal rat cardiomyocytes. Acta Pharmacol Sin 2010, 31:1569-1575.
89. Wang J.G., Jiang F.L., Feng J., et al. Study of inhibition of tanshinone II A on hypertrophy and apoptosis of cardiomyocytes induced by Ang II. Chin J Mod Med 2007, 17:2202-2204.
90. Yan L., Liang Q.S., Yong Y.Q., et al. The effect of tanshinone II A on JAK/STAT pathway of rat hypertrophic model induced by abdominal aorta coarctation in rats. Shi Yong Yi Xue Za Zhi 2008, 24:2199-2201. (in Chinese).
91. Tan X., Li J., Wang X., et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/Nfatc3 pathway. Int J Biol Sci 2011, 7:383-389.
92. Wang Z.H., Liang Q.S., Zheng Z. The effect of tanshinone on L-type calcium current in hypertrophic myocardium. Chin J Hypertens 2006, 14:450-454.
93. Xu C.Q., Lou Y.P., Yang B.F., et al. Correlation analysis of tanshinone IIA's inhibition of L-type calcium current and its shortening of action potential duration in cardiomyocytes of guinea pig. Chin Pharmacol Bull 1998, 14:428-431.
94. Yang R.F., Liu A.J., Ma X.J., et al. Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 2008, 51:396-401.
95. Zhou G.Y., Jiang W., Zhao Y., et al. Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria. Biochem Pharmacol 2003, 65:51-57.
96. Hong H.J., Liu J.C., Chen P.Y., et al. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. Int J Cardiol 2010, 10.1016/j.ijcard.2010.12.012.